Closing Expert Perspectives on Treatment in Advanced NSCLC
Lung cancer experts share final thoughts on their thorough discussion of treatments in NSCLC and what to look for in the future.
Emerging Antibody Drug Conjugates in the Lung Cancer Treatment Landscape
Dr Martin Dietrich gives an overview of novel antibody-drug conjugates in the NSCLC treatment landscape.
Recent Advances in Treatment of ROS1-Rearranged NSCLC
Hatim Hussain, MD, explains emerging data on ROS1 rearrangements in NSCLC and his approach to treatment in his clinical practice.
Updates in Treatment of NSCLC with ALK Rearrangements
Oncologists review data from the ALTA-1L clinical trial and CROWN study on therapies for the treatment of ALK rearrangements.
Treatment Selection and Sequencing for Patients with NTRK Fusions in Clinical Practice
A panel of lung cancer experts illustrate their personal clinical experience with treatment selection and sequencing for treating patients who have NTRK fusions.
Recent Advances in Treatment of NSCLC with NTRK Fusions
Misako Nagasaka, MD, PhD, provides an overview of clinical trial data on treatments for NTRK fusion–positive lung cancer.
Treatment of KRAS G12C Mutant NSCLC
Benjamin Levy, MD, explains KRAS G12C mutations in non–small cell lung cancer, and Hatim Husain, MD, provides insight into the mechanism of action of G12C inhibitors.
Recent Advances in Treatment of MET Exon 14 Skipping Mutations in NSCLC
Dr Martin Dietrich provides an overview of how to treat MET exon 14 skipping mutations in non–small cell lung cancer.
Updates in Treatment of HER2 Mutant NSCLC
Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.
Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC
Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.
Updates in Treatment of NSCLC with Classical EGFR Mutations
A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.
Challenges Associated with Molecular Testing in NSCLC
A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.
Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?
A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.
Liquid Biopsies in the NSCLC Molecular Testing Algorithm
Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.
Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice
Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512